Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irozee is a hematinic combination supplement developed and marketed by Bennet Pharmaceuticals. It is primarily indicated for the treatment and prevention of iron deficiency anemia and other nutritional deficiencies, particularly during pregnancy and lactation. The formulation typically includes carbonyl iron, which provides a high concentration of elemental iron with a favorable safety profile and high bioavailability; folic acid (Vitamin B9), essential for DNA synthesis and red blood cell maturation; cyanocobalamin (Vitamin B12), a vital co-factor for erythropoiesis; and zinc sulfate, which supports immune function and various enzymatic processes. By replenishing these essential nutrients, Irozee helps to improve hemoglobin levels and overall metabolic health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Irozee.